CYTX will validate the observations of sustained benefit in the ongoing P3 pivotal trial in the US as it is encouraging to see maintenance of the response in patients at a full two years after only a single administration!
Average values at the two-year timeframe for all four of these end points were statistically significantly improved over baseline and similar to improvements observed at one year. As with the previous studies, no safety issues related to Cytori Cell Therapy were reported.
CYTX closed -$0.01 at $0.36 and is UP in the pre-market +$0.01. News flow has picked-up and CYTX should be feeling the effect of positive results– BUY. I always love good beginnings as they foretell and fulfil the hope of … sustained improvement in four key endpoints of treatment. CYTX has FINALLY found the right mix of focus and should be … REWARDED.